This dual behavior reflects an insufficient anti-inflammatory counterbalance in the tumor-driven pro-inflammatory environment, where compensatory increases in IL-4 and IL-10 may become saturated, thereby limiting their regulatory capacity and contributing to cancer-related cognitive dysfunction [73,74]. The gene discussed is IL10; the disease is cancer.